PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30279231-0	2019	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.	Platinum	22-30	CREB binding protein	Homo sapiens	113-116	
30279231-9	2019	Importantly, cotherapy of CBP/beta-catenin antagonist PRI-724 induced sensitization of RBMS3-deleted EOC to platinum therapy.	Platinum	108-116	CREB binding protein	Homo sapiens	26-29	
18571892-11	2009	The siRNA directed to the TBCE gene and CBP/p300-interacting transactivator gene enhanced the cytotoxicity of diplatin to the platinum-resistant ovarian cancer cell line KFR.	Platinum	126-134	CREB binding protein	Homo sapiens	40-48	
32254583-3	2018	Herein, a novel SMND of carboplatin-lauric acid nanoparticles (CBP-LA NPs) was developed for the first time to reduce GSH-mediated platinum resistance and improve the antitumor efficiency of platinum(ii).	Platinum	131-139	CREB binding protein	Homo sapiens	63-66	
32254583-3	2018	Herein, a novel SMND of carboplatin-lauric acid nanoparticles (CBP-LA NPs) was developed for the first time to reduce GSH-mediated platinum resistance and improve the antitumor efficiency of platinum(ii).	Platinum	191-199	CREB binding protein	Homo sapiens	63-66	
32254583-10	2018	The intracellular glutathione determination and the Pt-DNA adduct assay revealed that CBP-LA NPs could reduce the intracellular GSH levels and improve the efficiency of platinum chelating with DNA, which would overcome GSH-mediated platinum(ii) resistance.	Platinum	52-54	CREB binding protein	Homo sapiens	86-89	
32254583-10	2018	The intracellular glutathione determination and the Pt-DNA adduct assay revealed that CBP-LA NPs could reduce the intracellular GSH levels and improve the efficiency of platinum chelating with DNA, which would overcome GSH-mediated platinum(ii) resistance.	Platinum	169-177	CREB binding protein	Homo sapiens	86-89